4th Quarter - Report

TARPLIN, DOWNS & YOUNG, LLC for SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION)

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

**see addendum pagebudget resolution, reconciliation, deficit reduction, debt ceiling, government shutdown, Continuing Resolution H.J.Res. 59, Continuing Appropriations Resolution, 2014

Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."1

LobbyistCovered position, as disclosed
RAISSA H DOWNS —
MICHELLE P EASTON —
ISAAC A FORDJOUR —
LINDA E TARPLIN —
JENNIFER B YOUNG —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: H.J.Res. 59 (113th)

Health Issues HCR

**see addendum pageHealth care reform, drug importation, 340b, biosimilars PL 111-148 - The Patient Protection and Affordable Care Act, PL 111-152 - The Reconciliation Act of 2010, implementation PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation H.R. 2186 - Valid Compounding Act H.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013, track and trace S. 959 - Pharmaceutical Compounding Quality and Accountability Act, track and trace H.R. 3204 The Drug Quality and Security Act H.R. 2725, S. 1413 - Safety Over Sequester Act, user fee sequester relief H.R. 1281/S. 1417 - Newborn Screening Saves Lives Reauthorization Act ***no specific bills, importation, Prescription Drug User Fee Act Renewal and associated policies, supply chain integrity, user fee sequester

Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."

LobbyistCovered position, as disclosed
RAISSA H DOWNS —
MICHELLE P EASTON —
ISAAC A FORDJOUR —
LINDA E TARPLIN —
JENNIFER B YOUNG —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 1919 (113th), H.R. 2186 (113th), H.R. 3204 (113th), S. 1417 (113th), H.R. 2725 (113th), H.R. 1281 (113th), S. 1413 (113th), S. 959 (113th)

Medicare/Medicaid MMM

**see addendum pagePL 111-148 - The Patient Protection and Affordable Care Act, implementation, ESRD, clinical laboratory payment H.R. 351/S. 351 - Protecting Seniors' Access to Medicare Act of 2013, IPAB H.R. 2810 Medicare Patient Access and Quality Improvement Act of 2013, SGR S. 1871 - SGR Repeal and Medicare Beneficiary Access Act of 2013 ***, no specific bill(s), implementation of QIP and MIPPA ESRD bundling provisions, Medicare Reimbursement, Medicaid Rebate, Medicaid reimbursement, quality indicators, deficit reduction

Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."

LobbyistCovered position, as disclosed
RAISSA H DOWNS Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst.
MICHELLE P EASTON Chief Health Counsel, Sen. Cmte. On Finance;
ISAAC A FORDJOUR —
LINDA E TARPLIN Congressman Billy Tauzin
JENNIFER B YOUNG Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg.

Contacted: SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: S. 1871 (113th), S. 351 (113th), H.R. 351 (113th), H.R. 2810 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.